Streetbeat News

Regulatory

ABBV

AbbVie's small cell lung cancer treatment, an antibody drug conjugate, has been granted FDA orphan designation. This designation is significant for AbbVie as it can provide benefits like market exclusivity and tax credits.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 7:12 pm

KBE

KRE

XLF

U.S. Treasury Secretary Yellen acknowledges the heavy regulatory compliance burdens on banks and emphasizes the importance of robust capital and liquidity requirements. She hopes for tailored regulations to ease smaller banks' burdens.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 7:04 pm

BTCUSD

El Salvador's 'Freedom Passport' initiative, aimed at attracting Bitcoin investors by offering residency visas, has not issued any passports since its launch in December 2023, despite government goals. This raises questions about the program's management and transparency.

Portfolio Pulse from Murtuza Merchant

October 29, 2024 | 6:46 pm

SPY

President Biden delivers remarks on his Investing in America agenda, which may have implications for the broader US economy and stock market.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 6:23 pm

CCL

Holland America Line has adjusted its 2026 Grand World Voyage route to avoid the Red Sea due to evolving regional situations. The new route includes stops in eight countries and a Panama Canal transit.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 5:53 pm

COIN

Coinbase's revenue may be negatively impacted due to lower trading volumes and regulatory uncertainty, according to analysts.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 5:49 pm

NVS

The FDA has granted accelerated approval to Novartis's drug Asciminib for treating Philadelphia chromosome-positive chronic myeloid leukemia. Clinical trials showed a 25% major molecular response rate at 24 weeks, outperforming Bosutinib's 13%.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 5:35 pm

ALLO

Allogene Therapeutics shares rose after the FDA granted Regenerative Medicine Advanced Therapy designation for ALLO-316, a treatment for advanced renal cell carcinoma.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 4:56 pm

NWN

The Oregon Public Utility Commission (OPUC) approved Northwest Natural's rate case, phasing out the line extension allowance by 2027, and ordered a $13.7M rate base reduction. The revenue requirement increases by $93.3M, with an adjusted rate base of $2.09B. New rates will begin on November 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 4:48 pm